Switch theme
Sign up to access all valuation multiples
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
2005
104
LTM Revenue $13.6M
Last FY EBITDA -$7.8M
$81.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adocia has a last 12-month revenue (LTM) of $13.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Adocia achieved revenue of $10.5M and an EBITDA of -$7.8M.
Adocia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adocia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | XXX | $10.5M | XXX | XXX | XXX |
| Gross Profit | $13.6M | XXX | $9.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$7.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -74% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$8.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -79% | XXX | XXX | XXX |
| Net Profit | -$10.5M | XXX | -$10.5M | XXX | XXX | XXX |
| Net Margin | -77% | XXX | -100% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Adocia's stock price is EUR 4 (or $4).
Adocia has current market cap of EUR 67.9M (or $76.3M), and EV of EUR 72.2M (or $81.1M).
See Adocia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81.1M | $76.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Adocia has market cap of $76.3M and EV of $81.1M.
Adocia's trades at 7.8x EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate Adocia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adocia has a P/E ratio of -7.3x.
See valuation multiples for Adocia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76.3M | XXX | $76.3M | XXX | XXX | XXX |
| EV (current) | $81.1M | XXX | $81.1M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.3x | XXX | -7.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdocia's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Adocia's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adocia's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Adocia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -74% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 167% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adocia acquired XXX companies to date.
Last acquisition by Adocia was XXXXXXXX, XXXXX XXXXX XXXXXX . Adocia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Adocia founded? | Adocia was founded in 2005. |
| Where is Adocia headquartered? | Adocia is headquartered in France. |
| How many employees does Adocia have? | As of today, Adocia has 104 employees. |
| Is Adocia publicy listed? | Yes, Adocia is a public company listed on PAR. |
| What is the stock symbol of Adocia? | Adocia trades under ADOC ticker. |
| When did Adocia go public? | Adocia went public in 2012. |
| Who are competitors of Adocia? | Similar companies to Adocia include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Adocia? | Adocia's current market cap is $76.3M |
| What is the current revenue of Adocia? | Adocia's last 12 months revenue is $13.6M. |
| What is the current EV/Revenue multiple of Adocia? | Current revenue multiple of Adocia is 6.0x. |
| Is Adocia profitable? | Yes, Adocia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
